An example of the clinical selectivity of regadenoson for the A2a adenosine receptor.
Miyamoto
Michael I
MI
Mission Internal Medical Group, Mission Viejo, CA, USA.
Clarke
Kyle A
KA
Thomas
Gregory S
GS
Belardinelli
Luiz
L
D000241:Adenosine / Q000494:pharmacology; D058908:Adenosine A2 Receptor Agonists / Q000494:pharmacology; D058917:Adenosine A2 Receptor Antagonists / Q000494:pharmacology*; D000368:Aged; D054316:Biomarkers, Pharmacological; D055426:Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; D005080:Exercise Test; D006801:Humans; D008297:Male; D055414:Myocardial Perfusion Imaging; D011687:Purines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D043705:Receptor, Adenosine A2A / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology
D058908:Adenosine A2 Receptor Agonists; D058917:Adenosine A2 Receptor Antagonists; D054316:Biomarkers, Pharmacological; D011687:Purines; D011720:Pyrazoles; D043705:Receptor, Adenosine A2A; D014665:Vasodilator Agents; C430916:regadenoson; D000241:Adenosine